4DMT’s Experimental Gene Therapy Cuts Eylea Use in Phase II Wet AMD Trial
Topline results from a mid-stage study show that 4D Molecular Therapeutics’ investigational gene therapy cut annual rates of Eylea injections by 85% and 89% for the low and high doses, respectively.
